Botulinum Toxin commonly known as BOTOX® — Competitive Intelligence Brief

Botulinum Toxin commonly known as BOTOX® (Botulinum Toxin commonly known as BOTOX®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurotoxin; acetylcholine release inhibitor. Area: Neurology; Aesthetics; Pain Management.

phase 3 Neurotoxin; acetylcholine release inhibitor SNARE complex proteins (SNAP-25, VAMP, syntaxin) Neurology; Aesthetics; Pain Management Small molecule

Target snapshot

Botulinum Toxin commonly known as BOTOX® (Botulinum Toxin commonly known as BOTOX®) — NYU Langone Health. Botulinum toxin blocks the release of acetylcholine at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Botulinum Toxin commonly known as BOTOX® TARGET	Botulinum Toxin commonly known as BOTOX®	NYU Langone Health	phase 3	Neurotoxin; acetylcholine release inhibitor	SNARE complex proteins (SNAP-25, VAMP, syntaxin)
Nuceiva	BOTULINUM TOXIN TYPE A	GlaxoSmithKline K.K.	marketed	Acetylcholine Release Inhibitor [EPC]	Synaptosomal-associated protein 25	2019-01-01
Xeomin	INCOBOTULINUMTOXINA	Merz Pharms	marketed	Acetylcholine Release Inhibitor [EPC]		2015-01-01
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Myobloc	RIMABOTULINUMTOXINB	Elan Pharm	marketed	Acetylcholine Release Inhibitor [EPC]		2009-01-01
Botulinum neurotoxin (BTX)	Botulinum neurotoxin (BTX)	The University of Texas Health Science Center, Houston	marketed	Neurotoxin; acetylcholine release inhibitor	SNARE proteins (SNAP-25, VAMP, syntaxin)
Placebo / Botulinum Toxin A	Placebo / Botulinum Toxin A	Walter Reed Army Medical Center	marketed	Neurotoxin / Acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurotoxin; acetylcholine release inhibitor class)

1. Allergan · 2 drugs in this class
2. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
3. Croma-Pharma GmbH · 1 drug in this class
4. NYU Langone Health · 1 drug in this class
5. The University of Texas Health Science Center, Houston · 1 drug in this class